BRUSSELS (Reuters) – European Union leaders aim to send a “clear signal” to U.S. President-elect Donald Trump at a summit on Thursday about their continued support for Ukraine and will also discuss the security and economic challenges posed by his return to the White House. The leaders will host Ukrainian President Volodymyr Zelenskiy at the start of their talks in Brussels and will reaffirm their “unwavering commitment” to supporting Ukraine “for as long as it takes”, according to draft conclusions. Trump has repeatedly called for a swift end to the nearly three-year-old war. On Monday he said Zelenskiy should be…
Author: user
In addition to these sales, Jaime gifted 100,000 shares to his spouse, as noted in the filing. This transaction did not involve any monetary exchange. Following these transactions, Jaime retains direct ownership of 3,660 shares and indirect ownership through trusts and his spouse. InvestingPro analysis shows the company maintains strong fundamentals with a GREAT financial health score and analyst price targets ranging from $37 to $40. Subscribers can access 16 additional ProTips and comprehensive valuation metrics in the Pro Research Report. InvestingPro analysis shows the company maintains strong fundamentals with a GREAT financial health score and analyst price targets ranging…
Earlier, on December 14, Mikan had acquired 35,000 shares of common stock through the vesting of restricted stock units, though this transaction did not involve any cash exchange. Following these transactions, Mikan’s direct ownership stands at 83,029 shares. With a current market capitalization of $34.58 million, the company faces some financial challenges, including cash burn concerns and short-term obligations exceeding liquid assets, according to recent financial data. With a current market capitalization of $34.58 million, the company faces some financial challenges, including cash burn concerns and short-term obligations exceeding liquid assets, according to recent financial data. Earlier, on December 14,…
(Reuters) -The Bank of Japan kept interest rates steady on Thursday, as policymakers preferred to tread cautiously in pushing up borrowing costs amid uncertainty over U.S. president-elect Donald Trump’s economic plans. As widely expected, the nine-member BOJ board decided to keep its short-term policy rate unchanged at 0.25%. But hawkish board member Naoki Tamura dissented and proposed raising interest rates to 0.5% on the view inflationary risks were building. His proposal was voted down. QUOTES: BART WAKABAYASHI, TOKYO BRANCH MANAGER, STATE STREET, TOKYO “They probably want to wait till next year and want some more solid information coming in on…
By Ankur Banerjee SINGAPORE (Reuters) -Asian stocks slipped and the dollar was perched near a two-year high on Thursday after the U.S. Federal Reserve cautioned it would ease the pace of rate cuts in the coming year, while the Bank of Japan kept rates steady, as expected. The yen weakened to touch a one-month low of 155.43 per dollar after the decision. The yen is down more than 8% this year against the dollar and is set for a fourth straight year of decline. The BOJ’s decision comes as the yen hovers around the 155 per dollar mark, the weaker…
The Bank of Japan (BOJ) headquarters is seen beyond the cherry blossoms in Tokyo on March 20, 2023.Kazuhiro Nogi | Afp | Getty ImagesThe Bank of Japan on Thursday held its benchmark interest rate steady at 0.25%.The decision comes a day after the U.S. Federal Reserve cut rates by 25 basis points, bringing the federal funds rate to 4.25%-4.5%.The yen weakened 0.16% against the dollar after the rate decision, trading at 155.06.The BOJ said in its statement that the decision to hold was a split 8-1 decision, with board member Naoki Tamura advocating for a 25-basis-points hike.The central bank did…
By Rae Wee SINGAPORE (Reuters) -The dollar flirted with a two-year peak on Thursday after the Federal Reserve signalled a slower pace of rate cuts in 2025, while the yen blipped lower after the Bank of Japan (BOJ) stood pat on rates. The BOJ kept interest rates steady on Thursday as expected, underscoring policymakers’ preference to spend more time scrutinising whether wage hikes will broaden and keep inflation durably around its 2% target. The yen fell in the immediate aftermath of the decision, weakening roughly 0.3% against the dollar to a one-month low of 155.28, before paring some of those…
SEATTLE—HomeStreet, Inc. (NASDAQ:) director Sidney Craig Tompkins (NYSE:) recently made a significant purchase of the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, Tompkins acquired 5,000 shares on December 17, 2024, at an average price of $11.4925 per share. The total value of the transaction amounted to approximately $57,462. The purchase comes as HomeStreet trades at a price-to-book ratio of 0.38, significantly below historical averages according to InvestingPro data. Following this purchase, Tompkins holds 5,000 shares indirectly through a defined benefit plan, as noted in the filing. Additionally, Tompkins has direct ownership of…
In recent transactions, American Strategic Investment Co. (NYSE:NYC) saw significant stock purchases by Nicholas S. Schorsch and affiliated entities. On December 16, 17, and 18, a total of 2,517 shares of Class A common stock were acquired, amounting to $22,451. The purchases were made at prices ranging from $8.78 to $9.01 per share. According to InvestingPro data, the company currently trades at a significant discount to its Fair Value, though it maintains a weak overall financial health score. Nicholas S. Schorsch, a prominent figure in the company, is the sole managing member of Bellevue Capital Partners (WA:), LLC, which is…
The findings from the CBL-0204 Phase 2b clinical trial have been selected for presentation at IMCAS, the premier global congress in aesthetic medicine. The data will be highlighted in both the 2025 focus session on advances in fat reduction therapies and further detailed in the Non-surgical Body Contouring session through an oral presentation.The CBL-0204 Phase 2b results underscore the remarkable efficacy and safety profile of CBL-514 for localized adipose reduction. Both primary and secondary endpoints were met, establishing CBL-514 as the potentially first injectable therapy for large-area fat reduction. This trial was also the first trial adopted FDA-recommended metrics, including…